Primary Objective:~• To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.~Secondary Objectives:~To establish the pharmacokinetic (PK) profile of orally administered TP-3654~To observe patients for any evidence of antitumor activity of TP-3654 by objective radiographic assessment~To study the pharmacodynamic effects of TP-3654 therapy~To establish the Recommended Phase 2 Dose (RP2D) for future studies with TP-3654
TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.